Parkinson's Disease Research
Parkinson's disease (PD) is a degenerative disease of the central nervous system that often impairs motor skills, speech, and other functions. Symptoms of the disease include resting tremor, bradykinesia and rigidity. The primary symptoms are the result of decreased stimulation of the motor cortex by the basal ganglia, normally caused by the insufficient formation and action of dopamine, which is produced in the dopaminergic neurons of the brain. Symptoms of the disease appear once 50-80% of dopamine neurons have died. Parkinson's disease is both chronic and progressive.
Parkinson's Disease Research Products Targets
- Adenosine A2B Receptor (7)
- Adenosine A2A Receptor (11)
- Caspase (9)
- Bcl-2 Family (13)
- Voltage-gated Calcium Channel (CaV) (38)
- GABAB Receptor (28)
- Others (23)
- Cyclooxygenase (24)
- D4 Receptor (12)
- STIM-Orai Channel (4)
- Ryanodine Receptor (6)
- Hsp90 (10)
- Hsp70 (4)
- 5-HT7 Receptor (11)
- 5-HT6 Receptor (14)
- 5-ht5 Receptor (2)
- 5-HT4 Receptor (17)
- Glutamate (Metabotropic) Group III Receptor (26)
- Glutamate (Metabotropic) Group II Receptor (33)
- Glutamate (Metabotropic) Group I Receptor (54)
- AMPA Receptor (45)
- GABAA-ρ Receptor (8)
- GABAA Receptor (66)
- Nicotinic (α7) Receptor (25)
- Nicotinic (α4β2) Receptor (14)
- D3 Receptor (12)
- LRRK2 (4)
- Catechol O-Methyltransferase (3)
- Vesicular Monoamine Transporter (4)
- NMDA Receptor (87)
- Kainate Receptor (22)
- IP3 Receptor (2)
- D2 Receptor (14)
- D1 and D5 Receptor (16)
- Trk Receptor (13)
- Trace Amine 1 Receptor (2)
- Adenosine A3 Receptor (8)
- Adenosine A1 Receptor (12)
- Monoamine Oxidase (10)
- M5 Receptor (2)
- M4 Receptor (3)
- M3 Receptor (4)
- M2 Receptor (5)
- M1 Receptor (8)
- Adrenergic α2 Receptor (33)
- Adrenergic α1 Receptor (22)
- Adrenergic β3 Receptor (12)
- Adrenergic β2 Receptor (6)
- Adrenergic β1 Receptor (7)
- Protein Arginine Methyltransferase (2)
Products for Parkinson's Disease Research - Page 67
- Cat.No. Product Name Information/Activity
-
BCC6888
E4CPG
E4CPG is a novel group I/group II metabotropic glutamate receptor antagonist, more potent than (RS)-MCPG .
-
BCC7345
Fenobam
Fenobam is a selective, orally active, and non-competitive mGluR5 antagonist acting at an allosteric modulatory site (Kd values are 54 and 31 nM for rat and human recombinant mGlu5 receptors, respectively). Fenobam displays inverse agonist activity which blocks the mGlu5 receptor basal activity with an IC50 of 84 nM. Fenobam exerts anxiolytic activity.
-
BCC7166
HexylHIBO
334887-43-3
-
BCC7167
(S)-HexylHIBO
334887-48-8
-
BCC7332
JNJ 16259685
JNJ16259685 is a selective antagonist of mGlu1 receptor, and inhibits the synaptic activation of mGlu1 in a concentration-dependent manner with IC50 of 19 nM.
-
BCC6983
LY 367385
LY367385 is a highly potent and selective mGluR1a antagonist. LY367385 has an IC50 of 8.8 μM for inhibits of quisqualate-induced phosphoinositide (PI) hydrolysis, compared with > 100 μM for mGlu5a. LY367385 has neuroprotective, anticonvulsant and antiepileptic effects.
-
BCC7347
LY 456236 hydrochloride
338736-46-2
-
BCC7281
3-MATIDA
518357-51-2
-
BCC7756
(RS)-MCPG disodium salt
1303994-09-3
-
BCC6610
(RS)-MCPG
(RS)-MCPG (alpha-MCPG) is a competitive and selective group I/group II metabotropic glutamate receptor (mGluR) antagonist. (RS)-MCPG blocks theta-burst stimulation (TBS)-induced shifts in both juvenile and neonatal rat hippocampal neurons.


